Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)
Status: Recruiting
Location: See all (10) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Prospective study to evaluate the relevance of CALR allele burden monitoring as a molecular marker of disease progression.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• adults (age ≥18 years),
• affiliated to the national social security system,
• with CALR mutated myeloproliferative neoplasm diagnosed between 2006 - 2020,
• for which at least one sample is available at the time of diagnosis or before cytoreductive treatment,
• who signed the consent to participate in the study,
• included, or consenting to be included, in the national clinical-biological database of France Intergroupe Syndrome Myéloprolifératifs (FIM).
Locations
Other Locations
France
CHU Angers
RECRUITING
Angers
Chu Bordeaux
RECRUITING
Bordeaux
Chu Brest
RECRUITING
Brest
Ch Cholet
RECRUITING
Cholet
Ch Le Mans
RECRUITING
Le Mans
Ch Morlaix
RECRUITING
Morlaix
AP-HP Henri Mondor
RECRUITING
Paris
Chu Poitiers
RECRUITING
Poitiers
Ch Quimper
RECRUITING
Quimper
Chu Tours
RECRUITING
Tours
Contact Information
Primary
Laurane COTTIN, Doctor
Laurane.Cottin@chu-angers.fr
+33 2 41 35 53 53
Backup
Emma BLANCHET
EmBlanchet@chu-angers.fr
+33 2 41 35 63 38
Time Frame
Start Date: 2021-10-28
Estimated Completion Date: 2030-04-28
Participants
Target number of participants: 260
Treatments
Experimental: CALRSUIVI cohort
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Angers
Collaborators: Ligue contre le cancer, France